RxDoctor Payments DataLook up a doctor →

Julie Wendt, MD

Allergy · Scottsdale, AZNPI 1497738314

Payments from drug & device makers

$16,107in general payments, 2019–2025

Across 776 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2K
  • GSK$2K
  • Grifols USA, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Pfizer$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • plus $8K from 41 others

What the payments were for

  • Consulting fees$3282%
  • Food & beverage$15,47796%
  • Education$3032%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$136,656
Medicare patients
193
Services billed
10,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5026$134,097
Dupixent SyringeDupilumab16$87,001
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5013$86,967
XolairOmalizumab23$82,219
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$24,810
Epinephrine91$13,668
Montelukast Sodium157$1,660
Albuterol Sulfate HfaAlbuterol Sulfate70$1,346
Cromolyn Sodium25$629
Azelastine Hcl12$465
Levofloxacin15$315
Fluticasone Propionate11$260
Triamcinolone Acetonide14$205
Hydroxyzine Hcl11$191
Methylprednisolone13$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$745$134,09726 claims
Bio Products Laboratory USA, Inc.Gammaplex$142$86,96713 claims
Genentech, Inc.Xolair$210$82,21923 claims
GSKTrelegy Ellipta$1,530$24,81029 claims
Cycle Pharmaceuticals IncCromolyn Sodium$17$62925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other allergy in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →